西妥昔单抗治疗结直肠癌肝转移研究进展

 结直肠癌肝转移发病率很高。目前，对结直肠癌肝转移患者的治疗，不管肝转移灶是否可手术切除，均推荐实施新辅助化疗后再行肝转移灶切除术。分子靶向治疗药物西妥昔单抗联合以奥沙利铂或伊立替康为主的化疗作为结直肠癌肝转移的二线或一线治疗方案，可获得较高的有效率和良好的远期生存，并使更多的患者得到肝转移灶切除的机会，提高肝转移灶切除率，但只推荐应用于k-ras基因为野生型的结直肠癌肝转移患者。

Advancement of cetuximab combined with chemotherapy in the treatment of liver metastases from colorectal cancer

High incidence of liver metastases from colorectal cancer was found. To the patients with liver metastases from colorectal cancer, regardless of whether the liver metastases could be resected or not, hepatectomy after neoadjuvant chemotherapy was recommended. The combination of cetuximab and chemotherapy based on irinotecan and oxaliplatin as the second-line and first-line for the liver metastases from colorectal cancer could get higher response and longer survival, and more patients got the chance of hepatectomy. However, cetuximab was only good for the colorectal cancer patients with wild-type k-ras.